Immunai joins 10x Genomics program to boost drug development
Together, the two companies say can give drugmakers a better view at the cellular level of how a patient’s immune system is responding to a cerain therapy.
Immunai decloaks with $20M in seed funding to map immune system with machine learning
The company, led by an ex-Palantir engineer and a former Harvard postdoctoral researcher, has developed machine learning algorithms to identify nuances in cells, mechanisms of action and biomarkers that could aid immunotherapy and cell therapy development.
presented by
What Keeps Healthcare CIOs Up at Night: Balancing Technology Investments with Consumer Expectations
When it comes to managing inbound phone calls, underperformance has devastating cost implications.